Neuromodulation Devices for Migraine: Cefaly, gammaCore, and Nerivio Explained

Neuromodulation refers to the use of electrical or magnetic energy to alter the activity of the nervous system. In migraine, several neuromodulation devices have been developed and received regulatory approval as tools for either preventing attacks or treating them acutely. These devices offer an option for people with migraine who want to reduce their reliance on medications, who cannot tolerate standard migraine medications due to side effects, or who have contraindications to pharmacological treatments.

Understanding what neuromodulation devices are available, how they work, what the evidence shows for their effectiveness, and who might benefit from them helps people with migraine and their healthcare providers evaluate whether these options are appropriate additions to a migraine management plan.

Cefaly — Transcutaneous Supraorbital Nerve Stimulation

Cefaly is a headband-shaped device worn across the forehead that delivers transcutaneous electrical stimulation to the supraorbital and supratrochlear branches of the trigeminal nerve. It received FDA clearance for migraine prevention in 2014, making it the first neuromodulation device to receive this clearance, and later received clearance for acute migraine treatment.

The proposed mechanism involves desensitization of trigeminal pain pathways through repeated electrical stimulation, reducing the excitability of the trigeminal system over time. For prevention, Cefaly is used daily for twenty-minute sessions. Clinical trials have demonstrated statistically significant reductions in migraine days per month with daily preventive use of Cefaly compared to sham stimulation.

gammaCore — Non-Invasive Vagus Nerve Stimulation

gammaCore is a handheld device that delivers non-invasive electrical stimulation to the vagus nerve through the skin of the neck. It received FDA clearance for acute and preventive treatment of episodic cluster headache and for acute treatment of migraine.

The vagus nerve has extensive projections to the brainstem pain-modulating systems including the nucleus tractus solitarius, which connects to the trigeminal nucleus caudalis. Stimulation of the vagus nerve may activate descending pain inhibitory pathways and reduce trigeminal nociception through these connections. Clinical trials have shown mixed results for migraine, with some studies demonstrating benefit for acute migraine treatment compared to sham stimulation.

Nerivio — Remote Electrical Neuromodulation

Nerivio is a wearable device worn on the upper arm that delivers remote electrical stimulation to peripheral sensory nerves in the arm. It received FDA clearance for acute treatment of migraine with and without aura and for prevention. The device is controlled through a smartphone app and delivers stimulation for forty-five minutes per treatment session.

The proposed mechanism is conditioned pain modulation, a process in which stimulation of peripheral sensory pathways activates descending inhibitory systems in the brainstem that reduce pain transmission at other sites including the trigeminal nucleus caudalis. Randomized controlled trials have demonstrated significant reductions in pain intensity and associated migraine symptoms compared to sham stimulation when used for acute treatment.

Choosing Among Neuromodulation Options

The choice among neuromodulation devices depends on several factors including the patient's primary need for acute versus preventive treatment, device availability and cost, insurance coverage, and personal preference regarding the form factor and usage requirements. All three devices discussed here require consistent use to achieve benefit — irregular use is less effective than systematic use according to each device's protocol.

Neuromodulation devices are generally considered complementary to rather than replacements for pharmacological treatment, though they may be appropriate as primary treatments for patients who prefer to minimize medication use.

Accessing Neuromodulation Devices

All three devices require a prescription in the United States. Insurance coverage varies by plan and device. Cefaly has a direct-to-consumer pathway through its website that includes a brief online consultation with a healthcare provider. Nerivio is available through a smartphone app following a telehealth consultation. gammaCore requires a prescription from a treating physician.

Patients interested in neuromodulation devices should discuss them with their neurologist or headache specialist, who can advise on which device is most appropriate for their specific migraine pattern and treatment history.